Abstract: The present invention relates to a SorCS2 crystal structure, the atomic coordinates obtained by X-ray crystallography of same, and their use in molecular modelling. The invention further relates to methods of growing crystals of SorCS2. Furthermore, the invention relates to peptides capable of binding to SorCS2, as well as their use as medicament, for example in the treatment of frontotemporal dementia.

Abstract: The present disclosure relates to inhibitors of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) for the treatment of lipoprotein metabolism disorders.

Abstract: The present disclosure relates to use of heparin analogues as inhibitors of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) for the treatment of lipoprotein metabolism disorders.

Abstract: The present disclosure relates to use of heparin analogues as inhibitors of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) for the treatment of lipoprotein metabolism disorders.

Abstract: The present disclosure relates to inhibitors of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) for the treatment of lipoprotein metabolism disorders.

Abstract: The present disclosure relates to inhibitors of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) for the treatment of lipoprotein metabolism disorders.

Abstract: The present disclosure relates to use of heparin analogues as inhibitors of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) for the treatment of lipoprotein metabolism disorders.

Abstract: The present disclosure relates to inhibitors of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) for the treatment of lipoprotein metabolism disorders.

Abstract: The present invention relates to a method to increase the survival of neurons by modulating the interaction between Sor LA and GDNF-family ligand receptors. The agent used to modulate the interaction between the SorLA and GDNF-family ligand receptors are selected from proteins, peptides, antibodies or small organic compounds. The invention also relates to a pharmaceutical compositions comprising these agent as well as the use of said agent or pharmaceutical composition in the treatment of a disease associated with the loss of neurons and/or wherein the survival of neurons are desired.

Abstract: The present invention relates to a method to increase the survival of neurons by modulating the interaction between SorLA and GDNF-family ligand receptors. The agent used to modulate the interaction between the SorLA and GDNF-family ligand receptors are selected from proteins, peptides, antibodies or small organic compounds. The invention also relates to a pharmaceutical compositions comprising these agent as well as the use of said agent or pharmaceutical composition in the treatment of a disease associated with the loss of neurons and/or wherein the survival of neurons are desired.

Abstract: The present invention provides a Sortilin crystal and methods for growing said crystal. The invention furthermore provide methods for design of specific ligands based on the crystal structure of Sortilin. The present invention also relates to the preparation and use of such ligands for the preparation of a medicament for the treatment of disease, damage or disorders of the central and peripheral nervous systems.

Abstract: The present invention provides a Sortilin crystal and methods for growing said crystal. The invention furthermore provide methods for design of specific ligands based on the crystal structure of Sortilin. The present invention also relates to the preparation and use of such ligands for the preparation of a medicament for the treatment of disease, damage or disorders of the central and peripheral nervous systems.